Floatz logo

Olaparib

BRCA 1 /2 and / or HRD

Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the BRCA 1 /2 and / or HRD cohort.

Asset / SponsorPhaseRating
Carboplatin
GBG Forschungs GmbH
Phase 2B
Epirubicin
GBG Forschungs GmbH
Phase 2B
Cyclophosphamide
GBG Forschungs GmbH
Phase 2B
syn818
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase 1CC

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →